keyword
MENU ▼
Read by QxMD icon Read
search

anti-tnf

keyword
https://www.readbyqxmd.com/read/28105709/the-impact-of-co-existing-immune-mediated-on-phenotype-and-outcomes-in-inflammatory-bowel-diseases
#1
G Conway, G Velonias, E Andrews, J J Garber, V Yajnik, A N Ananthakrishnan
BACKGROUND: Inflammatory bowel diseases lead to progressive bowel damage and need for surgery. While the increase in prevalence of other immune-mediated diseases in IBD is well recognised, the impact of this on the natural history of IBD is unknown. AIM: To determine the impact of concomitant immune-mediate disease on phenotypes and outcomes in IBD. METHODS: Patients with IBD enrolled in a prospective registry were queried about the presence of other immune-mediated diseases, defined as those where immune dysregulation plays a role in pathogenesis...
January 20, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28104989/trefoil-factor-3-is-not-a-useful-marker-of-mucosal-healing-in-crohn-s-disease-treated-with-anti-tnf-%C3%AE-antibodies
#2
Piotr Eder, Kamila Stawczyk-Eder, Katarzyna Korybalska, Natasza Czepulis, Joanna Luczak, Liliana Lykowska-Szuber, Iwona Krela-Kazmierczak, Krzysztof Linke, Janusz Witowski
AIM: To evaluate whether repeated serum measurements of trefoil factor-3 (TFF-3) can reliably reflect mucosal healing (MH) in Crohn's disease (CD) patients treated with anti-tumor necrosis factor-α (anti-TNF-α) antibodies. METHODS: Serum TFF-3 was measured before and after anti-TNF-α induction therapy in 30 CD patients. The results were related to clinical, biochemical and endoscopic parameters. MH was defined as a ≥ 50% decrease in Simple Endoscopic Score for Crohn's disease (SES-CD)...
January 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28103201/different-effects-of-anti-tnf-alpha-biologic-drugs-on-the-small-bowel-macroscopic-inflammation-in-patients-with-ankylosing-spondylitis
#3
A Chitul, A M Voiosu, Mădălina Marinescu, Simona Caraiola, Adriana Nicolau, Georgeta Camelia Badea, Magda Ileana Pârvu, R A Ionescu, B R Mateescu, M R Voiosu, C R Băicuș, M Rimbaș
: Background&Aims: Considering the ability of anti-TNF alpha drugs to lower the burden intestinal inflammation in patients with inflammatory bowel disease (IBD), and the similarity between IBD and ankylosing spondylitis (AS) regarding inflammatory intestinal involvement, we aimed to investigate the impact of anti-TNF alpha biologic therapy on subclinical intestinal inflammation in AS patients. METHODS: Between January 2008 and December 2013, 38 AS patients and 23 controls were enrolled in the study and investigated with small bowel videocapsule endoscopy examination and ileocolonoscopy...
January 18, 2017: Romanian Journal of Internal Medicine, Revue Roumaine de Médecine Interne
https://www.readbyqxmd.com/read/28094756/treatment-modifying-factors-of-biologics-for-psoriatic-arthritis-a-systematic-review-and-bayesian-meta-regression
#4
REVIEW
Eric Druyts, Jacqueline B Palmer, Chakrapani Balijepalli, Keith Chan, Mir Sohail Fazeli, Vivian Herrera, Jeroen P Jansen, Jay J H Park, Steve Kanters, Andreas Reimold
OBJECTIVES: The aim of this study was to explore factors that modify treatment effects of non-conventional biologics versus placebo in patients with psoriatic arthritis. METHODS: A systematic literature review and meta-regression was conducted. The biologics included etanercept, infliximab, adalimumab, golimumab, certolizumab, ustekinumab, tocilizumab, anakinra, abatacept, rituximab, and secukinumab. Outcomes included American College of Rheumatology (ACR) 20 and 50, Psoriasis Area Severity Index (PASI) 75, and 36-Item Short Form Health Survey (SF-36) Physical and Mental Component Summaries (PCS and MCS)...
January 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28094754/comparable-therapeutic-potential-of-umbilical-cord-mesenchymal-stem-cells-in-collagen-induced-arthritis-to-tnf-inhibitor-or-anti-cd20-treatment
#5
Yue Sun, Wei Kong, Saisai Huang, Bingyu Shi, Hanyu Zhang, Weiwei Chen, Huayong Zhang, Cheng Zhao, Xiaojun Tang, Genhong Yao, Xuebing Feng, Lingyun Sun
OBJECTIVES: The effects of mesenchymal stem cell (MSC) transplantation on established collagen-induced arthritis (CIA) were evaluated and compared to biologic therapies. METHODS: CIA was induced with the immunisation of type II collagen (CII) in DBA/1 mice. Human umbilical cord MSC, anti-TNF antibody, rhTNFR:Fc fusion protein and anti-CD20 antibody were respectively injected intraperitoneally into CIA mice. Arthritis severity was assessed by clinical and histological scoring...
January 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28090641/in-vivo-quantitative-assessment-of-the-therapeutic-response-in-a-mouse-model-of-collagen-induced-arthritis-using-18-f-fluorodeoxyglucose-positron-emission-tomography
#6
Anupam Mitra, Smriti Kundu-Raychaudhuri, Christine Abria, Angelica Rona, Abhijit J Chaudhari, Siba P Raychaudhuri
BACKGROUND: Mouse collagen induced arthritis (CIA) is the most commonly used animal model to investigate underlying pathogenesis of autoimmune arthritis and to demonstrate therapeutic efficacy of novel drugs in autoimmune arthritis. The conventional read out of CIA are clinical score and histopathology, which have several limitations including (i) subjected to observer bias; (ii) longitudinal therapeutic efficacy of a new drug cannot be determined. Thus a robust, non-invasive, in vivo drug screening tool is currently an unmet need...
January 16, 2017: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/28089625/azathioprine-for-refractory-ulcerative-proctitis-a-retrospective-multicenter-study
#7
Anne-Laure Mallet, Guillaume Bouguen, Guillaume Conroy, Xavier Roblin, Jean-Bernard Delobel, Jean-François Bretagne, Laurent Siproudhis, Laurent Peyrin-Biroulet
BACKGROUND: Efficacy of azathioprine (AZA) in refractory ulcerative proctitis (UP) is unknown. METHODS: All patients treated with AZA for refractory UP in three referral centers between 2002 and 2012 were included. "Treatment success" in the long-term was defined as the absence of colectomy during follow-up, no need for anti-TNF during follow-up, no ongoing systemic steroids use, no adverse event leading to AZA withdrawal, and clinically quiescent disease at last follow-up...
December 13, 2016: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28078747/granulocyte-monocyte-apheresis-as-an-adjuvant-therapy-to-anti-tumor-necrosis-factor-drugs-for-ulcerative-colitis
#8
Iago Rodríguez-Lago, Laura Gómez-Irwin, Encarnación Fernández, Rebeca Higuera, José Luis Cabriada
Biologic anti-tumor necrosis factor (TNF) drugs have demonstrated their efficacy for the treatment of ulcerative colitis. Nevertheless, some patients will not respond to this therapy or will develop loss of response. Leukapheresis is the main non-pharmacological therapy for some immune-mediated diseases. The aim of our study was to describe our experience with this therapy in ulcerative colitis patients after loss of response to anti-TNF treatment. Leukapheresis was indicated in four patients with left-sided or extensive colitis because of partial response to biological therapy or secondary loss of response to it...
January 11, 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28077740/the-jarisch-herxheimer-reaction-after-antibiotic-treatment-of-spirochetal-infections-a-review-of-recent-cases-and-our-understanding-of-pathogenesis
#9
REVIEW
Thomas Butler
Within 24 hours after antibiotic treatment of the spirochetal infections syphilis, Lyme disease, leptospirosis, and relapsing fever (RF), patients experience shaking chills, a rise in temperature, and intensification of skin rashes known as the Jarisch-Herxheimer reaction (JHR) with symptoms resolving a few hours later. Case reports indicate that the JHR can also include uterine contractions in pregnancy, worsening liver and renal function, acute respiratory distress syndrome, myocardial injury, hypotension, meningitis, alterations in consciousness, seizures, and strokes...
January 11, 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/28074487/higher-25-hydroxyvitamin-d-levels-are-associated-with-greater-odds-of-remission-with-anti-tumour-necrosis-factor-%C3%AE-medications-among-patients-with-inflammatory-bowel-diseases
#10
R W Winter, E Collins, B Cao, M Carrellas, A M Crowell, J R Korzenik
BACKGROUND: Vitamin D has been linked to disease activity among patients with inflammatory bowel diseases (IBD). Prior investigation has also suggested that vitamin D levels may affect duration of therapy with anti-tumour necrosis factor-α (anti-TNF-α) medications among patients with IBD. AIM: To evaluate the relationship between vitamin D levels and odds of reaching remission while on an anti-TNF-α medication. METHODS: A total of 521 IBD patients enrolled in the Brigham and Women's IBD Centre database were eligible for inclusion...
January 10, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28073801/predictors-of-work-disability-after-start-of-anti-tnf-therapy-in-a-national-cohort-of-swedish-patients-with-rheumatoid-arthritis-does-early-anti-tnf-therapy-bring-patients-back-to-work
#11
T Olofsson, I F Petersson, J K Eriksson, M Englund, J A Nilsson, P Geborek, L T H Jacobsson, J Askling, M Neovius
OBJECTIVES: To examine predictors of work ability gain and loss after anti-tumour necrosis factor (TNF) start, respectively, in working-age patients with rheumatoid arthritis (RA) with a special focus on disease duration. METHODS: Patients with RA, aged 19-62 years, starting their first TNF inhibitor 2006-2009 with full work ability (0 sick leave/disability pension days during 3 months before bio-start; n=1048) or no work ability (90 days; n=753) were identified in the Swedish biologics register (Anti-Rheumatic Treatment In Sweden, ARTIS) and sick leave/disability pension days retrieved from the Social Insurance Agency...
January 10, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28073137/-relapse-after-withdrawal-from-anti-tnf-therapy-for-inflammatory-bowel-disease
#12
Ulf Helwig
No abstract text is available yet for this article.
January 2017: Zeitschrift Für Gastroenterologie
https://www.readbyqxmd.com/read/28067896/pathogenic-role-of-endogenous-tnf-%C3%AE-in-the-development-of-sj%C3%A3-gren-s-like-sialadenitis-and-secretory-dysfunction-in-non-obese-diabetic-mice
#13
Jing Zhou, Toshihisa Kawai, Qing Yu
Patients with Sjögren's syndrome (SS), an autoimmune disease primarily affecting exocrine glands, exhibit enhanced TNF-α expression in the saliva and salivary glands. However, the precise in vivo role of TNF-α during the initiation and development of SS is not clearly defined. The present study is undertaken to determine the function of endogenously produced TNF-α in the pathogenesis of SS in non-obese diabetic (NOD) mice, a model of this human disease. Administration of a neutralizing anti-TNF-α antibody to female NOD mice during the stage prior to disease onset significantly improved salivary secretion, indicating a remission of clinical symptoms of SS...
January 9, 2017: Laboratory Investigation; a Journal of Technical Methods and Pathology
https://www.readbyqxmd.com/read/28067059/il-23-blockade-for-crohn-s-disease-next-generation-of-anti-cytokine-therapy
#14
Federica Furfaro, Daniela Gilardi, Mariangela Allocca, Clelia Cicerone, Carmen Correale, Gionata Fiorino, Silvio Danese
Adaptive immunity in intestinal inflammation may play a key role in the pathogenesis of Crohn's disease. In particular, interleukin (IL)-23 may be a key mediator in chronic intestinal inflammation by inducing the differentiation of naïve CD4+ T cells into Th17, with the production of several pro-inflammatory cytokines. Furthermore, IL-23 induces interferon-γ (IFN- γ) production from activated T cells, a critical cytokine in innate and adaptive immunity against infections. Areas covered: We aim to review the available data from literature regarding the role of IL-23, with a more specific focus on the recent progresses in the therapeutic modulation of this cytokine...
January 9, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28066859/the-long-term-outcome-of-anti-tnf-alpha-therapy-in-perianal-crohn-s-disease
#15
J Rayen, T Currie, R B Gearry, F Frizelle, T Eglinton
BACKGROUND: The aim of the present study was to evaluate the long-term outcomes of anti-tumour necrosis factor alpha therapy in perianal Crohn's disease and identify factors predicting response to treatment. METHODS: Data from hospital clinical records and coding databases were retrospectively reviewed from a tertiary care hospital in Christchurch, New Zealand. The study included 75 adult patients with perianal Crohn's disease commenced on anti-tumour necrosis factor alpha therapy from January 2000 to December 2012...
January 9, 2017: Techniques in Coloproctology
https://www.readbyqxmd.com/read/28064208/work-disability-in-non-radiographic-axial-spondyloarthritis-patients-before-and-after-start-of-anti-tnf-therapy-a-population-based-regional-cohort-study-from-southern-sweden
#16
Johan K Wallman, Anna Jöud, Tor Olofsson, Lennart T H Jacobsson, Henning Bliddal, Lars E Kristensen
OBJECTIVE: The aim was to assess work-loss days before and after commencement of anti-TNF treatment in patients with non-radiographic axial spondylarthritis (nr-axSpA). METHODS: Bionaïve nr-axSpA patients (n = 75), aged 17-62 years, fulfilling the Assessment of SpondyloArthritis international Society criteria for axial spondyloarthritis and starting anti-TNF treatment during 2004-11, were retrieved from the observational South Swedish Arthritis Treatment Group study...
January 7, 2017: Rheumatology
https://www.readbyqxmd.com/read/28063649/biologic-drugs-as-analgesics-for-the-management-of-osteoarthritis
#17
REVIEW
Theodoros Dimitroulas, Tosin Lambe, Rainer Klocke, George D Kitas, Rui V Duarte
BACKGROUND: Biologic drugs are novel therapeutic agents with demonstrated effectiveness in the management of a variety of chronic inflammatory disorders. Unmet needs in the treatment of chronic pain have led physicians to utilize a similar approach to patients suffering from conditions not characterized by systemic inflammation such as osteoarthritis (OA). The aim of this review is to discuss the current knowledge on the use of commonly used biologic agents [i.e., anti-tumor necrosis factor alpha (anti-TNF alpha) and anti-nerve growth factor (anti-NGF)] for the management of OA...
December 5, 2016: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28058024/short-term-effectiveness-of-golimumab-for-ulcerative-colitis-observational-multicenter-study
#18
Marta Maia Bosca-Watts, Xavier Cortes, Marisa Iborra, Jose Maria Huguet, Laura Sempere, Gloria Garcia, Rafa Gil, MariFe Garcia, Marga Muñoz, Pedro Almela, Nuria Maroto, Jose Maria Paredes
AIM: To evaluate the real-world effectiveness of golimumab in ulcerative colitis (UC) and to identify predictors of response. METHODS: We conducted an observational, prospective and multi-center study in UC patients treated with golimumab, from September 2014 to September 2015. Clinical activity was assessed at week 0 and 14 with the physician's global clinical assessment (PGA) and the partial Mayo score. Colonoscopies and blood tests were performed, following daily-practice clinical criteria, and the results were recorded in an SPSS database...
December 21, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28058018/factors-associated-with-surgery-in-patients-with-intra-abdominal-fistulizing-crohn-s-disease
#19
Shaul Yaari, Ariel Benson, Eyal Aviran, Naama Lev Cohain, Ran Oren, Jacob Sosna, Eran Israeli
AIM: To characterize radiological and clinical factors associated with subsequent surgical intervention in Crohn's disease (CD) patients with intra-abdominal fistulae. METHODS: From a cohort of 1244 CD patients seen over an eight year period (2006 to 2014), 126 patients were identified as having intra-abdominal fistulae, and included in the study. Baseline patient information was collected from the medical records. Imaging studies were assessed for: anatomic type and number of fistulae; diameter of the inflammatory conglomerate; length of diseased bowel; presence of a stricture with pre-stenotic dilatation; presence of an abscess; lymphadenopathy; and the degree of bowel enhancement...
December 21, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28056484/-biosimilars-in-inflammatory-bowel-disease-ibd-experiences-and-perceptions-of-german-gastroenterologists
#20
Bernd Bokemeyer, Axel Dignaß, Stefan Schreiber
The European Medicines Agency (EMA) recently approved the first anti-TNF-alpha biosimilar for infliximab (CT-P13) (trade names: Inflectra(®) and Remsima(®)) in Germany. Over the past year, German gastroenterologists gained experience treating IBD-patients with infliximab biosimilars (IFX-biosimilars). To evaluate their experiences and opinions on biosimilars, we conducted a nationwide online survey among German gastroenterologists. Our results are based on the assessment of 449 questionnaires. Although 61 % of the participants had already prescribed IFX-biosimilars, about two thirds of these participating gastroenterologists with IFX-biosimilar prescription stated their experience as based on fewer than 10 IBD-patients treated with IFX-biosimilars...
January 5, 2017: Zeitschrift Für Gastroenterologie
keyword
keyword
34737
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"